Education
About Us
Working with TipRanks
Follow Us
Genfit SA (GNFT)
NASDAQ:GNFT
See the Price Targets and Ratings of:
GNFT Financial Forecast
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$4
Hold
-3.61%
Downside
Reiterated
06/07/25
Genfit SA's overall stock score reflects a positive financial recovery with strong gross profit margins and enhanced cash flow generation. However, the high P/E ratio raises valuation concerns, and the technical indicators suggest a cautious short-term outlook. Strategic improvements in operating efficiency and capital structure are needed for sustainable growth.
H.C. Wainwright
$13
Buy
213.25%
Upside
Reiterated
02/07/25
Genfit SA's Promising Clinical Milestones and Financial Stability Underpin Buy RatingFrom ACLF The final Phase 1b dataset from a Phase 1b/2a study of GNS561 in CCA is also expected in 2025. Yesterday, GENFIT announced a list of its 2025 milestones that includes up to four clinical data readouts from its Acute on- Chronic Liver Failure (ACLF) programs. Recall, ACLF is a syndrome defined as the presentation of an acute liver injury in patients with different forms of chronic liver diseases, causing liver and extrahepatic organ failure. It has been estimated that about 137,000 ACLF patients are hospitalized annually in the 28-day mortality rate ranging from 23% to 74%.
Leerink Partners
―
Buy
―
Reiterated
01/30/25
Genfit SA (GNFT) Receives a Rating Update from a Top AnalystWe caught up with GNFT management earlier this month at a competitor conference (see our note HERE), where the company confirmed that proof-of-concept data for lead asset VS-01 in ACLF are expected in 2H25 (more details below). Beyond the royalty agreement, GNFT also announced plans to eliminate their outstanding convertible debt with OCEANE bondholders (~€56mn), which should provide further capital flexibility for the company moving forward. Overall, we view GNFT's royalty agreement with HCRx as a prudent strategic decision to place greater focus on the development of the company's rare liver disease pipeline. We expect 1H25 will be a period of clinical execution for GNFT with several trial initiations planned, and that data expected in 2H25 for VS-01 could provide important derisking for the pipeline. Reiterate OP.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$4
Hold
-3.61%
Downside
Reiterated
06/07/25
Genfit SA's overall stock score reflects a positive financial recovery with strong gross profit margins and enhanced cash flow generation. However, the high P/E ratio raises valuation concerns, and the technical indicators suggest a cautious short-term outlook. Strategic improvements in operating efficiency and capital structure are needed for sustainable growth.
H.C. Wainwright
$13
Buy
213.25%
Upside
Reiterated
02/07/25
Genfit SA's Promising Clinical Milestones and Financial Stability Underpin Buy RatingFrom ACLF The final Phase 1b dataset from a Phase 1b/2a study of GNS561 in CCA is also expected in 2025. Yesterday, GENFIT announced a list of its 2025 milestones that includes up to four clinical data readouts from its Acute on- Chronic Liver Failure (ACLF) programs. Recall, ACLF is a syndrome defined as the presentation of an acute liver injury in patients with different forms of chronic liver diseases, causing liver and extrahepatic organ failure. It has been estimated that about 137,000 ACLF patients are hospitalized annually in the 28-day mortality rate ranging from 23% to 74%.
Leerink Partners
―
Buy
―
Reiterated
01/30/25
Genfit SA (GNFT) Receives a Rating Update from a Top AnalystWe caught up with GNFT management earlier this month at a competitor conference (see our note HERE), where the company confirmed that proof-of-concept data for lead asset VS-01 in ACLF are expected in 2H25 (more details below). Beyond the royalty agreement, GNFT also announced plans to eliminate their outstanding convertible debt with OCEANE bondholders (~€56mn), which should provide further capital flexibility for the company moving forward. Overall, we view GNFT's royalty agreement with HCRx as a prudent strategic decision to place greater focus on the development of the company's rare liver disease pipeline. We expect 1H25 will be a period of clinical execution for GNFT with several trial initiations planned, and that data expected in 2H25 for VS-01 could provide important derisking for the pipeline. Reiterate OP.
Best Analysts Covering Genfit SA
1 Month
xxx
Success Rate
8/17 ratings generated profit
Average Return
-3.47%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 47.06% of your transactions generating a profit, with an average return of -3.47% per trade.
3 Months
xxx
Success Rate
7/17 ratings generated profit
Average Return
-6.96%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 41.18% of your transactions generating a profit, with an average return of -6.96% per trade.
1 Year
2 Years
xxx
Success Rate
9/17 ratings generated profit
Average Return
-2.56%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 52.94% of your transactions generating a profit, with an average return of -2.56% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GNFT Analyst Recommendation Trends
Rating
Jul 24
Sep 24
Oct 24
Jan 25
Feb 25
Strong Buy
4
5
4
3
2
Buy
1
1
0
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
6
4
4
3
Each month's total comprises the sum of three months' worth of ratings.
GNFT Stock Forecast FAQ
What is GNFT’s average 12-month price target, according to analysts?
Based on analyst ratings, Genfit SA’s 12-month average price target is 13.00.
What is GNFT’s upside potential, based on the analysts’ average price target?
Genfit SA has 213.25% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GNFT a Buy, Sell or Hold?
Genfit SA has a consensus rating of Moderate Buy which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
What is Genfit SA’s price target?
The average price target for Genfit SA is 13.00. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $13.00 ,the lowest forecast is $13.00. The average price target represents 213.25% Increase from the current price of $4.15.
The highest analyst price target is $13.00 ,the lowest forecast is $13.00. The average price target represents 213.25% Increase from the current price of $4.15.
What do analysts say about Genfit SA?
Genfit SA’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 0 Wall Streets Analysts.
How can I buy shares of GNFT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.